Follow on Google News News By Tag Industry News * Pharmaceutical * More Industries... News By Location Country(s) Industry News
Follow on Google News | Biosimilars are not Generics is to be discussed at SMi's Biosimilars and Biobetters conferenceWith billions of dollars worth of biologic drugs going off patient in the next decade, this industry is set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount.
By: SMi Group Testimonials “Great conference, right size and mix of people” - Senior Manager, Biogen Idec “Very well organised, excellent time keeping [...] excellent choice of topic covered” - Patent Editor, IMS Health This year’s key presentations include: Next generation monoclonal antibody development and clinical challenges with biosimilar drug development - Frank Scappaticci, Associate Group Medical Director, Genentech The developing biosimilars regulatory framework in the U.S. - Ross Lobell, Vice President, Regulatory Affairs, Medimmune Factors to be considered for Biosimilar CMC development - Hans-Martin Mueller, Associate Director, Biotech Development, Merck GCSF biosimilar case study - Matthew Turner, Global Medical Leader - Zarzio and Binocrit, Sandoz Biopharmaceuticals Biosimilar sales forecast in seven unregulated markets in 2016: How large is the opportunity? Register by 31st May and receive a £300 discount! # # # Biosimilars and Biobetters is just one of the many conferences that are a part of the SMi Group portfolio. The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|